Peculiarities of the antiapoptotic Bcl-2 protein expression in liver in a model of obesity and type 2 diabetes and with linaglyptin correction
Background. XXI century is known as a century of obesity and type 2 diabetes (T2D), one of the main reasons of nonalcoholic fatty liver disease (NAFLD). Severe forms of NAFLD, such as non-alcoholic steatohepatitis and cirrhosis, are associated with process of apoptosis. A great contributor in the de...
Guardado en:
Autor principal: | M. A. Cherepanova |
---|---|
Formato: | article |
Lenguaje: | RU |
Publicado: |
Scientific Сentre for Family Health and Human Reproduction Problems
2018
|
Materias: | |
Acceso en línea: | https://doaj.org/article/885df33e57d1482cb29c0868ac9d9967 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Expert committee on novel DPP-4 inhibitor TRADJENTA (linagliptin) in treatment of type 2 diabetes mellitus
por: Editorial team Diabetes Mellitus
Publicado: (2012) -
Effect of Switching from Linagliptin to Teneligliptin Dipeptidyl Peptidase-4 Inhibitors in Older Patients with Type 2 Diabetes Mellitus
por: Han E, et al.
Publicado: (2020) -
New prospects in the treatment of diabetes mellitus
por: Minara Shamkhalovna Shamkhalova, et al.
Publicado: (2012) -
Influence of type-4 dipeptidyl peptidase inhibition on endothelium-dependent relaxation of aortae from a db/db mouse model of type 2 diabetes: a comparison with the effect of glimepiride
por: Woodman OL, et al.
Publicado: (2019) -
Urate-lowering effects of dipeptidyl peptidase-4 inhibitors
por: Taras S. Panevin, et al.
Publicado: (2020)